SPY299.08+3.64 1.23%
DIA250.25+5.37 2.19%
IXIC9,340.22+15.63 0.17%

Mersana Therapeutics Q1 EPS $(0.350) Beats $(0.370) Estimate, Sales $11.000K Miss $390.000K Estimate

Mersana Therapeutics (NASDAQ:MRSN) reported quarterly losses of $(0.350) per share which beat the analyst consensus estimate of $(0.370) by 5.41 percent. This is a 150 percent decrease over earnings of $0.700 per share

Benzinga · 05/08/2020 10:07

Mersana Therapeutics (NASDAQ:MRSN) reported quarterly losses of $(0.350) per share which beat the analyst consensus estimate of $(0.370) by 5.41 percent. This is a 150 percent decrease over earnings of $0.700 per share from the same period last year. The company reported quarterly sales of $11.000 thousand which missed the analyst consensus estimate of $390.000 thousand by 97.18 percent. This is a 99.97 percent decrease over sales of $41.035 million the same period last year.